Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Москва
Список исп. литературыСкрыть список 1. Adelman LC, Adelman JU, von Seggern R, Mannix LK. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache 2000; 40 (7): 572–80. 2. Alves C, Cachola I, Brandao J. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Prim Care Psychiat 1999; 5: 57–63. 3. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a metaanalysis of studies against tricyclic antidepressants. J Psychopharmacol 1994; 8: 238–49. 4. Anderson IM, Tomenson BM. Treatment discontinuation with SSRI compared with TCA: a metaanalysis. Brit Med J 1995; 310: 1433–8. 5. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a metaanalysis of efficacy and tolerability. Depression Anxiety 1998; 7 (Suppl. 1): 11–7. 6. Arana JW, Rosenbaum JF. Handbook of psychiatric drug therapy. Philadelphia, 2001. 7. Ballus C, Quiros G, de-Flores T et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder of dysthymia. Internat Clin Psychopharmacol 2000; 15: 43–8. 8. Barkin RL, Barkin S. The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Am J Ther 2005; 12 (5): 431–8. 9. Benedictis E. Double–blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Psychopharmacol 2000; 14: 61–6. 10. Benkert O, Gruender G, Wetzel H et al. A randomised, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiat Res 1996; 30: 441–51. 11. Blythe D, Hackett LP. Cardiovascular and neurological toxicity of Venlafaxine. Human & Experimental Toxicology 1999; 18: 309–13. 12. Bradley RH, Barkin RL, Jerome J et al. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003; 10 (5): 318–23. 13. Buckley NA, McManus PR. Fatal toxicity of serotonergic and other antidepressant drugs: analysis of UK mortality data. BMJ 2002; 325: 1332–3. 14. Burnett F, Dinan T. Venlafaxine. Pharmacology and Therapeutic Potential in the Treatment of Depression. Human Psychopharmacol 1998; 13: 153–62. 15. Blier P. Possible neurobiological mechanisms underlying faster onset of antidepressant action. J Clin Psychiat 2001; 62 (suppl 4): 7–11. 16. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871–80. 17. Bymaster FP, Katner JS, Nelson DL et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27: 699–711. 18. Cardona X, Avila A, Castellanos P. Venlafaxine-Associated Hepatitis 2000; Ann Intern Med 132 (5): 417; Horsmans Y, De Clercq M, Sempoux C. Venlafaxine-associated hepatitis [Letter]. Ann Intern Med 1999; 130: 944. 19. Cheeta S, Schifano F, Oyefeso A et al. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998–2000. Br J Psychiat 2004; 184: 41–7. 20. Clayton AH, Pradko JF, Croft HA et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiat 2002; 63 (4): 357–66. 21. Clerc GE, Ruimy P, Verdeau PJ. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalised for major depression and melancholia, international. Clin Psychopharmacol 1994; 9: 139–43. 22. Costa, e. Silva J. Randomised, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiat 1998; 59: 352–7. 23. Cunningham L, Borison R, Carman J et al. A comparison of venlafaxine, trazodone and placebo in major depression. J Clin Psychopharmacol 1994; 14: 99–106. 24. Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Internat Clin Psychopharmacol 1995; 10: 15–20. 25. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 1986; 90: 131–8. 26. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affective Disorders 1990; 18: 289–99. 27. Delgado PL, Charney DS, Price LH et al. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiat 1990; 47: 411–8. 28. Derivan A, Entsuah AR, Kikta D. Venlafaxine: measuring the onset of antidepressant action. Psychopharm Bull 1995; 31 (2): 439–47. 29. Deshauer D. Venlafaxine (Effexor): concerns about increased risk of fatal outcomes in overdose. J Canad Med Assoc 2007; 176 (1): 39–40. 30. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiat 1996; 20 (1): 57–71. 31. Dwight MM., Arnold LM, O\'Brien H et al. An Open Clinical Trial of Venlafaxine Treatment of Fibromyalgia. Psychosomatics 1998; 39: 14–7. 32. Edwards G. Selective serotonin reuptake inhibitors: a modest though welcome advance in the treatment of depression. BMJ 1992; 304: 1644–5. 33. Einarson A, Fatoye RNB, Sarkar M et al. Pregnancy Outcome Following Gestational Exposure to Venlafaxine: A Multicenter Prospective Controlled Study Am J Psychiat 2001; 158: 1728–30. 34. Entsuah R, Derivan A, Kikta D. Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients. Clin Ther 1998; 20 (3): 517–26. 35. Entsuah AR, Rudolph RL, Hackett D, Miska S. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol 1996; 11 (2): 137–45. 36. Fantaskey A, Burkhart KK. A case report of venlafaxine toxicity. J Toxicol Clin Toxicol 1995; 33: 359–61. 37. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiat 1994; 55 (Suppl. A): 62–8; discussion 69–70, 98 100. Rev. 38. Fleisch MC, Blauer F, Gubler JGH, Kuhn M. Eosinophilic pneumonia and respiratory failure associated with venlafaxine treatment. Eur Respire J 2000; 15: 205–8. 39. Galvez R, Caballero J, Atero M et al. Venlafaxine extended release for the treatment of chronic pain. A series of 50 cases. Actas Esp Psiquiat 2004; 32 (2): 92–7. 40. Geddes JR, Freemantle N, Mason J et al. SSRIs versus alternative antidepressants for depressive disorders. Cochrane Library, issue I. Oxford: Update Software. 2001. 41. Geerts S, Lacante P, Migon A. Venlafaxine versus fluoxetine in the treatment of depressed patients with concomitant anxiety. J Eur Coll Neuropsychopharmacol 1999; 9 (suppl. 5): S224. 42. GentiI V, Kerr-Correa F, Moreno R et al. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Psychopharmacol 2000; 14: 61–6. 43. Goldberg HL, Finnerty R. An open-label, variable-dose study of WY-45,030 (venlafexine) in depressed outpatients. Psychopharmacol Bull 1988; 24 (1): 198–9. 44. Golden RN, Nicholas L. Antidepressant efficacy of venlafaxine. Depress Anxiety 2000; 12 (Suppl. 1): 45–9. Rev. 45. Gorman J, Laszlo A. Efficacy of Fenlafaxine in mixed Depression-Anxiety States. Depres Anxiety 2000; 12 (1): 77–80. 46. Gross G, Huber G. How far are newer antidepressants an advance compared with classical antidepressants? Neurol Psychiat Brain Res 1999; 7: 79–86. 47. Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacother 2004; 24 (5): 621–9. 48. Guelfi JD, White C, Hackett C et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psych 1995; 56 (10): 450–8. 49. Guelfi JD. Efficacy and Tolerability of Mirtazapine versus Venlafaxine in Hospitalised, Severely Depressed Patients with Melancholia [Abstract]. London: Association of Clinical Neuropsychopharmacology. 1999 50. Haro JM. Definind the scope of the problem: the prevalence of psychiatric disorders in Europe. Poster presented at the 15th ECNP Congress, October 2002, Barcelona, Spain. 51. Hendrick V, Altshuler L, Wertheimer A et al. Venlafaxine and Breast-Feeding. Am J Psychiat 2001; 158: 12. 52. Heninger G, Delgado P, Charney D. The revised monoamine theory of depression: a modulatory role of monoamines, based on new findings from monomaine depletion experiments in humans. Pharmacopsychiatry 1996; 29: 2–11. 53. Hirschfeld R. WPA teaching bulletin on depression 2000; 4 (19): 7–10. 54. Hollyday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49 (2): 281–94. 55. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psych 1996; 153: 151–62. 56. Joffe RT, Marshall AM, Lee DK. A large open-label study of venlafaxine in depressed outpatients by community-based physicians. J Clin Psychiat 1998; 59 (10): 515–20. 57. Judge R, Wagner B. Once-daily venlafaxine XR compared with fluoxetine in outpatient with depression and anxiety. J Clin Psychiat 1999; 60: 795–6. 58. Keller MB, Lavori PM, Mueller TI et al. Time to recovery, chronicity and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 sujects. Arch Gen Psychiat 1992; 49: 809–16. 59. Kennedy SH, Eisfeld BS, Dickens SE et al. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiat 2000; 61 (4): 276–81. 60. Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey replication (NCS-R). JAMA 2003; 289: 3095–105. 61. Khan A, Upton GV, Rudolph RL et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. J Clin Psychopharmacol 1998; 18 (1): 19–25. 62. Koski A, Vuori E, Ojanpera I. Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish. Int J Legal Med Nov 2005; 119 (6): 344–8. 63. Kroenke K, Messina N 3rd, Benattia I et al. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. J Clin Psychiat 2006; 67 (1): 72–80. 64. Kunz NR, Goli V, Entsuah R et al. Diabetic neuropathic pain management with venlafaxine extended release. Eur Neuropsychopharmacol 2000; 10 (3): 389. 65. Laux G, Dietmaier O, KЪnig W. Pharmakopsychiatrie. MЪnchen, 2001. 66. Lecrubier Y, Boutin M, Moon CAL et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiat Scandinavica 1997; 95: 485–93. 67. Markowitz JS, Patrick KS. Venlafaxine–tramadol similarities. Med Hypotheses 1998; 51 (2): 167–8. 68. McCue RE, Joseph M. Venlafaxine- and Trazodone-Induced Serotonin Syndrome. Am J Psychiat 2001; 158 (12): 2088–9. 69. McPartlin GM, Reynolds A, Anderson C et al. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Primary Care Psychiat 1998; 693: 127– 32. 70. Mahapatra SN, Hackett D. A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Internat J Clin Pract 1997; 51: 209-13. 71. Mehtonen O, Sogaard J, Roponen P et al. Randomised, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiat 2000; 61: 95-100. 72. Mendels J, Johnston R, Mattes J, Riesenberg R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose response study. Psychopharmacol Bull 1993; 29: 169-74. 73. Mitchell PB, Schweitzer I, Burrows G. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol 2000; 20 (4): 483-7. 74. Montgomery S. Why do we need new and better antidepressants? Medicographia 2005; 27 (3): 213-6. 75. Montigny C. de, Silverstrone PH et al. Venlafaxine in Treatment-Resistant Major Depression: A Canadian Multicenter, Open-Label Trial. J Clin Psychopharmacol 1999; 19: 401-6. 76. Morgan O, Griffiths C, Baker A et al. Fatal toxicity of antidepressants in England and Wales, 1993-2002. Health Stat Q 2004; 23: 18-24. 77. Murray C, Lopez A. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 1997; 349: 1436-42. 78. Nelson J, Mazure C, Bowers M et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiat 1991; 48: 303-7. 79. Nierenberg A, Feigner JP, Rudolph R. Venlafaxine for treatment resistant unipolar depression. J Clin Psychopharmacol 1994; 14: 419-23. 80. Nayer A De, Geerts S, Ruelens L et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 2002; 5 (2): 115-20. 81. O\'Hanlon JF, Robbe HWJ, Vesmeeren A et al. Venlafaxine\'s Effects on Healthy Volunteers\' Driving, Psychomotor, and Vigilance Performance During 15-Day Fixed and Incremental Dosing Regimens. J Clin Psychopharm 1998; 18 (3): 212-9. 82. Oliver JJ, Kelly C, Jarvie D et al. Venlafaxine poisoning complicated by a late rise in creatine kinase: two case reports. Hum Experim Toxicol 2002; 21: 463-6. 83. Parsons AT, Anthony RM, Meeker JE. Two fatal case of venlafaxine poisoning. J Analit Toxicol 1996; 20: 266-8. 84. Perry NK. Venlafaxine-induced serotonin syndrome with relapse following amitriptyline. Postgrad Med J 2000; 76: 254-6. 85. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Brit J Psychiat 1999; 175: 12-6. 86. Preskorn SH. Applied Clinical Psychopharmacology. J Pract Psych Behav Health 1999; 7: 224-8. 87. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharm 1996; 16 (3): 54-61. 88. Rudolph RL. Meta-Analysis of the Effects of Venlafaxine on anxiety associated With Depression. MD. J Clin Psychopharmacol 1998; 18: 212-21. 89. Rudolph R, Fabre L, Feighner J et al. A randomised, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. Clin Psychiat 1998; 59: 116-22. 90. Rudolph R, Feiger A. A double-blind, randomised, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1998; 56: 171-81. 91. Rakesh J. Single-Action Versus Dual-Action Antidepressants Prim Care Companion. J Clin Psychiat 2004; 6 (suppl. 1): 7-11. 92. Salinas E. Once-daily venlafaxine XR versus paroxetine outpatients with major depression, biological. Psychiatry 1997; 42 (suppl. I): 297S. 93. Samuelian JC, Hackett D. A randomised, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression. J Psychopharmacol 1998; 12: 273–8. 94. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine Treatment of Fibromyalgia. Ann Pharmacother 2003; 37 (11): 1561–5. 95. Schatzberg A, Cantillon M. Antidepressant early response and remission with venlafaxine or fluoxetine in depressed geriatric patients. Internat J Neuropsychopharmacol 2000; 3 (suppl. I), SI9I. 96. Schweizer E, Clary C, Weise C, Rickels K. An open-label, dose-finding study of WY-45,030, a novel bicyclic antidepressant. Psychopharmacol Bull, Jan 1988; 24 (1): 195–7. 97. Schweizer E, Weise C, Clary C et al. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991; 11 (4): 233–6. 98. Schweizer E, Feighner J, Mandos LA et al. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiat 1994; 55: 104–8. 99. Schweitzer I, Burrows G, Tuckwell V et al. Sustained response to open-label venlafaxine in drug-resistant major depression. J Clin Psychopharmacol 2001; 21 (2): 185–9. 100. Seth R, Jennings AL, Bindman J et al. Combination treatment of noradrenalin and serotonin reuptake inhibitors in resistant depression. Brit J Psychiat 1992; 161: 562–5. 101. Shaikir S. Data. Southampton, UK, Drug Safety Research Unit, 1999. 102. Shrivastava RK, Cohn C, Crowder J et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994; 14: 322–9. 103. Silverstone PH, Ravindran A. Once daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety Venlafaxine XR 360 Study Group. J Clin Psychiat 1999; 60: 22–8. 104. Silverstrone PH et al. Venlafaxine in Treatment-Resistant Major Depression: A Canadian Multicenter, Open-Label Trial. J Clin Psychopharmacol 1999; 19: 401–6. 105. Silverstone P, Entsuah R, Hackett D. Two items on the Hamilton Depressive Rating Scale are effective predictors of remission: comparison of SSRI with SNRI venlafaxin. Internat Clin Psychopharmacol 2002; 17: 273–80. 106. Smeraldi E, Rizzo F, Crespi G. Double blind, randomised study of venlafaxine, clomipramine and trazodone in geriatric patients with major depression. Primary Care Psychiat 1998; 4: 189–95. 107. Stahl SM. Does depression hurt? J Clin Psychiat 2002; 63 (4): 273–4. 108. Stanley N, Kimber S, Fairweather D et al. Venlafaxine and dothiepin in depressed patients: a comparison of efficacy and effect on cognition and subjective sleep [Abstract PI044]. Ilth European Congress of Neuropsychopharmacology Paris, France. 109. Sellers EM, Ball SE, Cheung SW et al. Inhibition by venlafaxine (VF) and other 5HT reuptake inhibitors of the polymorphic enzyme CYP2D6 [abstract]. 22nd Annual Meeting of the American College of Neuropsychopharmacology, Honolulu 1993 Dec. 13–17; 163. 110. Smith D, Dempser C, Glanville J et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reaptake inhibitors and other antidepressants: a metaanalysis. Br J Psychiat 2002; 180: 396–404. 111. Thase ME. Effects of venlafaxine on blood pressure: a meta–analysis of original data from 3744 depressed patients. J Clin Psychiat 1998; 59: 502–8. 112. Thase ME, Friedman ES, Howland RH. Venlafaxine and treatment-resistant depression. Depress Anxiety 2000; 12 (Suppl. 1): 55–62. 113. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatr 2001; 178: 234–41. 114. Thase ME, Clayton AH, Haight BR et al. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 2006; 26 (5): 482–8. 115. Tran P, Bymaster FP, McNamara RK et al. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 2003; 23: 78–86. 116. Troy SM, Turner MB. Pharmacokinetic and Pharmacodinamic Evaluation of the potential Drug interaction between Venlafaxine and Ethanol. 117. Tylee A, Beaumont G, Bowden MW et al. A double-blind, randomised, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Primary Care Psychiat 1997; 3: 51–8. 118. Tzanakaki M, Guazzelli M, Nimatoudis I et al. Increased remission rates with venlafaxine compared with fluoxetine in hospitalised patients with major depression and melancholia. Internat Clin Psychopharmacol 2000; 15: 29–34. 119. van Praag HM. Monoamines and abnormal behavior. A multiaminergic perspective. Brit J Psychiat 1990; 157 (11): 723–34. 120. White CM, Gailey RA, Levin GM, Smith T. Seizure resulting from a venlafaxine overdose. Ann Pharmacother 1997; 31: 178–80. 121. Wittchen H-U, Jacobi F. Size and burden of mental disorders in Europe-a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005; 15 (4): 357–76. 122. Zanardi R, Franchini L, Serretti A et al. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiat 2000; 61: 26–9. 123. Zimmer B, Kant R, Zeiller D et al. Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs. old patients with comorbid medical disorders. Int J Psychiat Med 1997; 27 (4): 353–64. 124. Андрусенко М.П. Антидепрессанты: соотношение особенностей нейрохимического действия и клинических эффектов при лечении депрессий. Псих. и психофарм. 2005; 5: 273–9. 125. Волель Б.А., Романов Д.В. Опыт применения венлафаксина (велафакса) у пациентов с депрессией в амбулаторной и клинической практике. 126. Козырев В.Н., Зеленина Е.В., Лебедева О.И. Эффективность и переносимость препарата Эфевелона (Венлафаксин) при терапии депрессивных расстройств. Псих. и психофарм. 2007; 9 (2). 127. Медведев В.Э., Добровольский А.В. Лечение депрессий у больных сердечно-сосудистыми заболеваниями (опыт применения велаксина). Псих. растр. общ. мед. 2007; 4 (в печати). 128. Мосолов С.Н. Клиническое применение современных антидепрессантов. СПБ., 1995. 129. Мосолов С.Н. Современный этап развития психофармакотерапии. В кн.: Новые достижения в терапии психических заболеваний. М., 2002; 21-37. 130. Раевский К.С. Антидепрессанты: нейрохимические аспекты механизма действия. Псих. и психофарм. 2001; 5: 162-6. 131. Смулевич А.Б. Депрессии в общей медицине. М., 2001. 132. Upadhyaya HP, Brady KT, Sethuraman G et al. Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol 2001; 21 (1): 116–8. 133. Bobes J, Gonzalez MP, Saiz PA, Bousono M. Venlafaxine in the treatment of depression in alcoholic patients. Comunicacion Poster presentada en el 21 Congress of the CINP (Abstract PW 16008). Glasgow, 1997. 134. Garcia-Portilla MP, Bascaran MT, Saiz PA et al. Effectiveness of venlafaxine in the treatment of alcohol dependence with comorbid depression. Actas Esp Psiquiat 2005; 33 (1): 41–5. 135. Tierney JG. II. Treatment-Resistant Depression: Managed Care Considerations. J Manag Care Pharm 2007; 13 (6) (suppl. S-a): S2–S7. 136. Gartlehner G, Hansen RA, Thieda P et al. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Comparative Effectiveness Review No. 7. Rockville, MD: Agency for Healthcare Research and Quality. 2007. 137. Gorman J, Laszlo A. Efficacy of Fenlafaxine in mixed Depression-Anxiety States. Depression and Anxiety, 2000; 12 (1): 77-80. 138. Judge R, Wagner B. Once-daily venlafaxine XR compared with fluoxetine in outpatientwith depression and anxiety. J Clin Psychiatry 1999; 60: 795-6. 139. Rudolph RL, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol. Apr;18(2):136-44. 1998. 140. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiat 1999; 60: 22–8.